CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
洞悉人异体 CAR-T 治疗：一个开放获取数据集
英文原题：Insight into human allogeneic CAR-T therapy: an open-access dataset.
查看英文原题
Insight into human allogeneic CAR-T therapy: an open-access dataset.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法在多种癌症中显示出显著疗效，但通常作为多线既往治疗后的后续治疗。与自体产品相比，异基因CAR-T 产品在细胞质量和成本效益方面具有独特优势。由于CAR-T 细胞与传统药物有本质区别，数学建模对于阐明其暴露-反应关系至关重要。然而，模型的实用性取决于稳健的参数化，而这需要高质量数据。尽管临床数据快速增加，但数据可及性有限且分散于不同来源，仍构成挑战。为解决这一限制，本研究构建了一个综合数据集，汇总了用于治疗血液系统疾病的异基因CAR-T 细胞临床试验。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy demonstrates significant efficacy in various cancers, predominantly as a subsequent treatment line following multiple prior therapies. When compared to autologous options, allogeneic CAR-T products offer distinct advantages related to cell quality and cost-effectiveness. Because CAR-T cells differ fundamentally from conventional pharmaceuticals, mathematical modeling is essential to elucidate their exposure-response relationships.
However, model utility depends on robust parametrization, which requires high-quality data. Although clinical data are expanding rapidly, challenges remain due to their limited availability and fragmentation across different sources. To address this limitation, this work introduces a comprehensive dataset aggregating human clinical trials that utilize allogeneic CAR-T cells for hematological disorders.
论文信息
- 作者
- Obajtek N、Lisowski B、Ulaszek S、Jesionek M、Piejko M、Polak S
- 单位
- Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland. Electronic address: natalia.obajtek@uj.edu.pl.Poland
- 文献类型
- 综述
- 期刊
- Drug discovery today2026 Jul
- 原文标识
- PubMed 42264430 · DOI 10.1016/j.drudis.2026.104714